Blog and News
Stay informed about how we help VA in delivering excellent clinical outcomes and patient care.We are presenting at The Fall 2023 DoD/VA & Govt HIT Summit on Oct 11-12, with our very own @David Whitmer to discuss “The Full Story Around the VA’s EHRM Program” with a focus on how the VA needs to continue to invest in, maintain, and upgrade VistA.
Read MoreDSS is proud to announce that it’s been named a finalist in the precisionFDA Veterans Cardiac Health and AI Model Predictions (V-CHAMPS) Challenge.
Read MoreLeading health information technology solutions providers DSS, Inc. and Iconic Data Inc. have deep experience in supporting the U.S. Department of Veterans Affairs’ mission of care to Veterans. Throughout the years, they have been helping the VA in evaluating and evolving its operations to maintain high standards in patient care.
Read MoreWe are presenting at The Spring 2023 DoD/VA & Govt HIT Summit on May 24-25, with our very own David Whitmer to discuss “VistA Modernization: An approach for evolution, not revolution” to help VA achieve their HIT goals and honor the commitment to providing the best care anywhere for Veterans.
Read MoreDSS showcased its vision for being a catalyst for innovation and mission critical information systems with a focus on suicide prevention, cutting-edge technology solutions, and helping the VA to advance its HRO goals at HIMSS23 last week.
Read MoreFrank Martinez, director of business analysis group at DSS, and Ruth Conway, clinical system analyst III at DSS, discuss how the DSS OTM solution supports the VA’s HRO journey, and much more.
Read MoreLearn more about how DSS is hosting a panel about suicide prevention in the care delivery setting at HIMSS 2023.
Read MoreDSS launched its newly refreshed Federal website to reflect how it is shaping the future of health care and advancing HRO goals for the Department of Veterans Affairs.
Read MoreAt ID Week 2022, VA executives presented a poster session titled, highlighting how high-risk patients with mild to moderate disease were identified as a group who would benefit from COVID-19 monoclonal antibody (mAB) treatment to mitigate progression to severe disease or hospitalization.
Read More
